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Abstract
Background: Data on the prevalence of and factors associated with nontuberculous mycobacteria (NTM) in
patients with non–cystic fibrosis (CF) bronchiectasis are limited. Our aim was to determine the prevalence and
factors associated with isolation of NTM in this population.
Methods: We performed a multicenter observational study of historical cohorts comprising consecutive patients
with non-CF bronchiectasis and at least 2 sputum samples cultured for mycobacteria over a period of 5 years.
Results: The study population included 218 adult patients (61.9 % women) with a mean (SD) age of 55.7 (16) years
and a mean (SD) of 5.1 (3.3) cultures/patient. NTM was isolated from sputum in 18 patients (8.3 %). Of these, 5
patients (28 %) met the American Thoracic Society criteria for NTM disease. Mycobacterium avium complex was the
most frequently isolated microorganism (9 patients, 4.1 %). The variables independently associated with isolation of
NTM were FVC ≥ 75 % predicted (OR, 4.84; 95 % CI 1.47 to 15.9; p < 0.05), age ≥ 50 years (OR, 4.74; 95 % CI 1.25 to
17.97; p < 0.05), and body mass index (BMI) ≤ 23 kg/m2 (OR, 2.97; 95 % CI 1.03-8.58; p < 0.05). Patients with these
three characteristics had a 40 % probability of having at least one isolation of NMT.
Conclusions: A significant number of patients with non-CF bronchiectasis are positive for the isolation of NTM. M.
avium complex is the most frequently isolated mycobacteria. FVC ≥ 75 % predicted, age ≥ 50 years, and a BMI ≤
23 kg/m2 were independently associated with the presence of NTM in patients with non-CF bronchiectasis.
Keywords: Nontuberculous mycobacteria, Disease prevalence, Non-cystic fibrosis bronchiectasis, Epidemiology
Abbreviations: BMI, Body mass index; CF, Cystic fibrosis; NTM, Nontuberculous mycobacteria; PPMs, Potential
pathogenic microorganisms
Background
Bronchiectasis is a chronic respiratory condition character-
ized by cough, sputum production, and increased suscepti-
bility to lower respiratory tract infections. Impairment of
mucus clearance facilitates recurrent respiratory infections
[1]. While the lower respiratory tract is normally sterile,
conditions such as bronchiectasis enable colonization by
microbes such as bacteria. However, the airways of patients
with bronchiectasis are also chronically colonized or in-
fected by microorganisms, such as yeasts, filamentous
fungi, and nontuberculous mycobacteria (NTM) [2]. NTM
are ubiquitous in water and soil. Most cases of human
infection are caused by NTM from the environment [3].
The incidence of lung colonization and infection due to
NTM in patients with cystic fibrosis (CF) and non-CF
bronchiectasis is increasing worldwide [4]. Since NTM
diseases are not notifiable, epidemiological data are not
readily available. The organism most frequently associated
with these infections is Mycobacterium avium complex
[5–7]. Isolation of pulmonary NTM does not necessarily
indicate advanced infection or “disease,” since NTM may
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be present in respiratory tract secretions with no evident
signs of illness (“colonization”). In pre-existing lung dis-
ease, especially in patients who experience frequent exac-
erbations (eg, those with bronchiectasis), defining clinical
and radiological criteria that are specific for NTM diseases
is more difficult.
Most published data on the prevalence of and factors
associated with NTM in bronchiectasis are obtained
from patients with CF. A recent meta-analysis by Chu et
al. showed that the overall prevalence of NTM was
9.3 % in patients with non-CF bronchiectasis. Neverthe-
less, data on patients with non-CF bronchiectasis are
limited, and most studies in this population have small
samples [7]. Therefore, the aims of the present study
were to determine the prevalence of NTM in a multi-
centre cohort of consecutive adult patients with non-CF
bronchiectasis and to determine factors that are inde-
pendently associated with isolation of NTM.
Methods
Study design
We performed an observational study of historical co-
horts from 4 Spanish teaching hospitals with multidis-
ciplinary and standardized non-CF bronchiectasis
outpatient clinics.
Study population
The study population comprised 296 consecutive
patients aged ≥ 18 years who had been diagnosed with
non-CF bronchiectasis of widely varying causes and
for whom radiological extension and clinical and
functional impairment were confirmed. Patients had
to have been followed for at least 5 years during the
period 2002–2010 before they could be considered for
inclusion in analysis.
Patients had to have at least 2 sputum samples cul-
tured for mycobacteria while (in a clinically stable
phase) during the 5 years after the diagnosis. Accord-
ing to the recommendations of the Spanish Society of
Pulmonology and Thoracic Surgery, the causes ruled
out in idiopathic bronchiectasis were as follows: im-
munodeficiency with evidence of defective antibody
production, gastroesophageal reflux disease, allergic
bronchopulmonary aspergillosis, mycobacterial infec-
tions prior to development or diagnosis of bronchiec-
tasis, cystic fibrosis, primary ciliary dyskinesia, and
α1-antitrypsin deficiency [8]. CF was ruled out by 2
negative sweat test results in patients with bronchiec-
tasis of unknown cause or a clinical presentation
compatible with CF [9]. The study was approved by
the Ethics and Research Committee of each center
(registration number of the coordinating center: 0088-
89-2011).
Diagnosis of bronchiectasis
Bronchiectasis was diagnosed based on a high-resolution
computed tomography scan of the chest that was inter-
preted by radiologists experienced in respiratory disor-
ders. Images were obtained in full inspiration (1-mm
collimation and 10-mm intervals from the apex to the
base of the lungs). The presence of bronchiectasis was
confirmed based on the criteria published by Naidich et
al. [10]. The extent of bronchiectasis was evaluated ac-
cording to the number of lobes affected, with the lingula
and middle lobe considered as independent lobes.
Data collection
Data were collected from all clinically stable patients
and included the following: age, gender, body mass index
(BMI, kg/m2), etiology, smoking habit (pack-years), dys-
pnea according to the modified Medical Research Coun-
cil scale, macroscopic appearance of sputum (percentage
of patients with purulent sputum), type of bronchiectasis
(cystic or noncystic), radiological findings (number of
lobes affected by bronchiectasis), and spirometry find-
ings (forced vital capacity [FVC] and forced expiratory
volume in the first second [FEV1] as both absolute
values and percent predicted). We also recorded hospi-
talizations secondary to severe exacerbations and the
number of exacerbations. All variables were obtained
within 6 months after the radiological diagnosis of bron-
chiectasis, except for hospitalizations and the number of
exacerbations, which were obtained prospectively during
the year after the radiological diagnosis. Long-term
treatments (antibiotics, oral macrolides, and oral cortico-
steroids) taken for at least 1 year after the radiological
diagnosis of bronchiectasis were also recorded.
One sputum sample was recovered every 6 months
during a clinically stable phase and cultured for
mycobacteria, bacteria, and fungi. Additional sputum
cultures were obtained whenever considered necessary
by the clinician.
A stable clinical situation was defined as the absence
of clinical criteria of exacerbation and no antibiotics or
corticosteroids in the preceding 4 weeks [11]. Exacerba-
tion was defined as the acute onset and persistence of
changes in sputum characteristics (increased volume,
thicker consistency, greater purulence, and hemoptysis)
and/or increased breathlessness unrelated to other
causes [12].
Microbiology
Each respiratory sample was collected under sterile con-
ditions and processed immediately or conserved at 4 °C.
Smears were stained using the auramine acid fast
method and scanned with microscopy fluorescence light
at × 200 and × 400. All respiratory samples were
processed according to the Tacquet-Tison technique.
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Processed samples were inoculated on Lowenstein-
Jensen, Coletsos, and liquid medium (VersaTREK,
formerly ESPII, Difco, Detroit, Michigan, USA). Cultures
were incubated at 37 °C for at least 8 weeks.
Classic phenotyping assays were used. A specific gene
probe for detection of M. avium complex was first used in
1990 (Accuprobe, GenProbe Inc., San Diego, California,
USA). In 2003, species identification was complemented
by 16S rRNA gene sequence analysis.
Sputum samples underwent auramine acid-fast stain-
ing and examination for routine bacteriological examin-
ation simultaneously. Only sputum samples with more
than 25 polymorphonuclear leukocytes and fewer than
10 squamous cells on Gram stain were considered valid
samples and processed for bacterial culture. Bacterial
chronic lung infection was defined as isolation of the
same potentially pathogenic microorganism (PPM) after
the diagnosis of bronchiectasis in >50 % of respiratory
cultures during the 5-year study period [13].
Statistical analysis
The statistical analysis was performed using SPSS, ver-
sion 15.0 (SPSS, Chicago, Illinois, USA). All data were
expressed as mean (SD) or median (IQR) for quantitative
variables and as absolute values and percentages for
qualitative variables. The normality of the distribution
was assessed using the Kolmogorov-Smirnov test. Preva-
lence of isolation of NTM was defined as the percentage
of patients with at least 1 positive culture for NTM dur-
ing the study. Patients were divided into 2 groups:
NTM-positive patients (those with at least 1 positive
sputum culture that showed growth of mycobacteria at
any visit) and NTM-negative patients. Depending on the
distribution of the variables, the t test or Mann-Whitney
test was used to compare 2 means, and the chi-square
test (with Fisher exact test if necessary) was used to
compare qualitative or dichotomous variables. Variables
of clinical interest (according to the current literature or
the researcher’s opinion) and those that presented statis-
tically significant differences (p <0.1) in the univariate
analysis were included as independent variables in a lo-
gistic regression model based on the backward stepwise
technique (Wald test). In order to determine the prob-
ability of having at least 1 isolation of NTM in different
patient profiles, ROC curves were used to dichotomize
continuous variables of special clinical interest according
to the researchers (age, FVC, and BMI). The cut-off
points were those with the greatest capacity to discrim-
inate between patients with and without NTM, as fol-
lows: FVC (%predicted, with a cut-off of 75 %), age (with
a cut-off of 50 years), and BMI (with a cut-off point of
23 kg/m2).
The independent variables that were finally included
were age ≥ 50 years, BMI ≤ 23 kg/m2, macroscopic
appearance of the sputum (mucoid vs mucopurulent or
purulent), FVC ≥ 75 %, and isolation of PPMs (apart
from NTM) from the sputum. The odds ratio (OR) and
confidence intervals (95 % CI) for the independent vari-
ables were also calculated. P values < 0.05 were consid-
ered statistically significant in the logistic regression
analysis.
A figure was constructed to show the different patient
profiles with their probabilities of having at least 1 isola-
tion of NTM depending of the presence or absence of
the dichotomized variables independently associated
with the isolation of NTM.
Results
Study population
Of the 296 patients screened, 218 met the eligibility
criteria and were included in the study. The mean (SD)
age of patients was 55.7 (16) years and 61.9 % were
women. FVC was 66.8 ± 21.6 % predicted, FEV1 62.6 ±
26.1 % predicted, and BMI 24.8 (4.6) kg/m2. All patients
had at least 2 sputum samples cultured for mycobacteria
during the 5-year study, with a mean of 5.1 (3.3) cul-
tures/patient. The most frequent known aetiology of
bronchiectasis was postinfectious causes (35.8 %),
followed by chronic obstructive pulmonary disease
(13.8 %), systemic diseases (12.8 %), immunodeficiency
(2.3 %), and primary ciliary dyskinesia (3.2 %). The aeti-
ology was unknown in 29.8 % of cases. Cystic bronchiec-
tasis was detected in 56 patients (25.7 %).
Prevalence of mycobacterial species
NTM was isolated at least once from sputum in 18
patients (8.3 %) and M. tuberculosis from 2 patients. M.
avium complex was the most frequently isolated micro-
organism (9 patients, 4.1 %). Other mycobacterial spe-
cies were recovered from 9 patients (4.1 %) and included
M. abscessus (3 patients), M. fortuitum (2), M. gordonae
(2), M. chelonae (1), M. lentiflavum (1), and M. simiae
(1). One patient had M. simiae and M. avium complex.
Smears were positive in 7 of the 218 eligible patients
(3.2 %). Of the 18 patients in whom NTM was isolated,
only 6 (33 %) were smear-positive, and 5 (28 %) met the
ATS/IDSA criteria for NTM lung disease [14] (3M.
avium complex, 1M. abscessus, 1M. chelonae) (Fig. 1).
Cohort characteristics and factors associated with
isolation and disease caused by NTM
When we compared the 5 patients who met the ATS/
IDSA criteria for NTM lung disease with the remaining
patients (213), we found that the 5 patients were women.
With respect to the remainder of the study population,
these 5 patients were less likely to present cystic bron-
chiectasis (0 vs 26 %, p = 0.001) or chronic bacterial
colonization (20 % vs 59 %; p = 0.01) and had better
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functional test results (FEV1 80.5 % vs 62.1 % [p = 0.035]
and FVC de 85 % vs 74 % (p = 0.0429). None of the 5 pa-
tients died during follow-up.
The characteristics of patients in the NTM-positive
and NTM-negative groups are shown in Table 1. Univar-
iate analysis revealed that patients with NTM were sig-
nificantly older (64 vs 54.9 years; p < 0.05) and tended to
be less frequently chronically infected with Pseudomonas
aeruginosa (28 % vs. 44 %), Haemophilus influenzae
(11 % vs. 23 %), and other PPMs (12 % vs. 45 %). In
addition, Aspergillus was more frequently isolated than
in culture-negative patients (39 % vs. 26 %), purulent
sputum was less frequent (41 % vs. 62 %), and lung func-
tion was better.
Table 2 shows the results of the fully adjusted logistic
regression analysis. Patients with isolation of NTM were
nearly 5 times as likely to be aged ≥ 50 years and have an
FVC > 75 % predicted value and nearly 3 times as likely
to have a BMI ≤ 23 kg/m2.
Figure 2 shows a patient profile probability tree for the
isolation of NTM at least once depending on the 3 vari-
ables independently related to isolation of NTM. The
patient profile with the greatest probability (40 %) of iso-
lation of NTM comprised all 3 characteristics (FVC pre-
dicted ≥ 75 %, age ≥ 50 years and BMI ≤ 23 kg/m2); the
patient profile with the lowest probability of isolation of
NTM (0 %) in our series comprised FVC < 75 % pre-
dicted and age < 50 years.
Discussion
Our study indicates that the prevalence of NTM isolates
is high in patients with non-CF bronchiectasis and that
M. avium complex is the most commonly isolated
microorganism. Based on our results, FVC ≥ 75 % pre-
dicted, age ≥ 50 years, and BMI ≤ 23 kg/m2 were inde-
pendently associated with the presence of NTM at least
once in patients with non-CF bronchiectasis. Further-
more, these patients tended to be less frequently chron-
ically infected by P. aeruginosa and H. influenzae.
Fig. 1 Number of patients with positive non-tuberculous mycobacterial
cultures (NTM), grouped by mycobacterial species. Patients who met
American Thoracic Society/Infectious Disease Society of America (ATS/
IDSA) microbiologic criteria for NTM disease are represented in the
shaded bars and those who did not meet ATS/IDSA criteria are
represented in solid bars. The patient with Mycobacterium simiae
also had M. avium complex (MAC)
Table 1 Patient characteristics for patients with and without
Non-tuberculous mycobacteria (NTM) cultured from their sputum






(n = 18) (n = 200)
Age, yra 64 (13.3) 54.9 (15.9) 0.02
Age≥ 50 years 15
(83.3 %)
126 (63 %) 0.06
Gender (% females)b 78 % 60 % 0.2
BMI, kg/m2a 23.5 (4.8) 24.9 (4.6) 0.24
BMI≤ 23 kg/m2b 11
(61.1 %)
65 (32.5 %) 0.034
Idiopathic 5 (27.8 %) 60 (30 %) 0.79
Post-infection 6 (33.3 %) 72 (36 %)
Systemic diseases 4 (22.2 %) 24 (12 %)
Immunodeficiency 1 (5.6 %) 4 (2 %)
COPD 2 (11.1 %) 28 (14 %)
Ciliary dyskinesia 0 7 (3.3 %)
Other 0 5 (2.5 %)
Smoking history (pack-years)c 22.2 (33) 11.6 (25.6) 0.2
Dyspnea (mMRC) 1.29 (1.3) 1.33 (1.13) 0.8
Macroscopic appearance of sputum
(muco-purulent or purulent)a
7 (39 %) 125
(62.5 %)
0.045
Cystic bronchiectasisb 4 (22 %) 52 (26 %) 0.7
Number of affected lobesa 2.9 (1.3) 2.6 (1.2) 0.2
FVC, % predicteda 82.5 (23) 73.5 (24) 0.09
FVC≥ 75 % predictedb 14
(77.8 %)
94 (47 %) 0.011
FEV1, % predicted
a 72.3 (26) 63 (25) 0.15
Chronic P. aeruginosa infectionb 5 (28 %) 88 (44 %) 0.1
Chronic H. influenzae infectionb 2 (11 %) 46 (23 %) 0.1
Chronic bacterial infection, other
PPMsb
2 (12 %) 90 (45 %) 0.05
Isolation of Aspergillus sppb 7 (39 %) 52 (26 %) 0.2
Macrolides (chronic use)b 3 (17 %) 22 (11 %) 0.4
Antibiotics (chronic use)b 4 (22 %) 70 (35 %) 0.2
Systemic steroids (chronic use) 1 (6 %) 8 (4 %) 0.6
Hospital admissionsc 0.5 (0.7) 0.7 (1.1) 0.5
Exacerbationsc 2.18 (1.7) 3 (2.1) 0.2
BMI body mass index, COPD chronic obstructive lung disease, mMRC modified
Medical Research Council, PPMs potentially pathogenic microorganisms
aExpressed as mean (SD)
bExpressed as frequency, number (%)
cExpressed as median (IQR)
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In the present study, the prevalence of NTM was
8.3 %, which is consistent with values reported previ-
ously in adult patients with non-CF bronchiectasis (2 to
37 %) [15–17]. Consistent with previous findings [7], M.
avium complex was the most frequently isolated patho-
gen. Again, as indicated by other authors [15, 16], it is
notable that smears were positive in only 33 % of pa-
tients with positive cultures.
Data on the natural history, prognosis, and associated
factors of adult patients with non-CF bronchiectasis and
coexisting NTM infection are limited, and most studies
were conducted in CF patients with bronchiectasis. In
both CF and non-CF patients, age is the only risk factor
clearly associated with NTM [17–19]. However, in the
present study, we found that other factors were associ-
ated with isolation of NTM. In this sense, NTM-positive
patients tended to have better lung function, lower BMI,
lower frequency of chronic P. aeruginosa infection, and
a higher frequency of Aspergillus. NTM-positive patients
also had fewer exacerbations and less frequently took
chronic antibiotic therapy. A previous report found that
NTM were more likely to be isolated in female patients
with low BMI [17].
We found that age ≥ 50 years and FVC ≥ 75 % pre-
dicted were independently associated with isolation of
NTM. The association between NTM and significantly
older age in patients with mild disease may be a
phenomenon of repeated, prolonged environmental ex-
posure that is not related to the severity of pulmonary
disease. Olivier et al. suggest that patients with more se-
vere lung disease could die before having sufficient ex-
posure time to acquire and retain mycobacteria [6].
Although several published reports on CF and non-CF
bronchiectasis patients found that lung function and
colonization by P. aeruginosa were positively, negatively,
or inconsequentially associated with the development of
NTM [15–17, 20–23], a large American multicenter
study in CF patients showed that patients who were
culture-positive for NTM were older, had milder disease,
and were more likely to be colonized with Staphylococcus
aureus but not with P. aeruginosa [6]. In the present
study, NTM-positive patients tended to have better lung
function and a lower frequency of chronic P. aeruginosa
infection. Aspergillus was also more frequently isolated in
this group. In fact, the factor most associated with the
presence of bronchiectasis was mild functional impair-
ment (FVC ≥ 75 % predicted). Patients with mild func-
tional impairment presented a greater prevalence of NTM
(13 %), making this variable the best predictor of isolation
of NTM. Given that P. aeruginosa infection has been asso-
ciated with worse pulmonary function and poor prognosis
[24, 25], NTM-positive patients in our study, who were
less commonly infected by P. aeruginosa, should have less
impaired pulmonary function and a longer life expectancy.
However, we cannot rule out the possibility that this
association results from the difficulty in recovering myco-
bacteria from sputum with P. aeruginosa despite decon-
tamination procedures [6, 26].
Although no clear association between NTM and Asper-
gillus spp has been demonstrated, several investigators have
reported that NTM infection is associated with Aspergillus-
related diseases in patients with non-CF bronchiectasis [18]
Table 2 Logistic regression showing the factors independently
associated with the presence of Non-tuberculous mycobacteria
in the sputum of patients with non-cystic fibrosis bronchiectasis
Variable B OR 95 % IC p
FVC≥ 75 % predicted 1.58 4.84 1.47–15.9 0.009
Age≥ 50 years 1.56 4.74 1.25–17.97 0.022
BMI≤ 23 kg/m2 1.09 2.97 1.03–8.58 0.045
Full adjusted model include: FVC ≥ 75 % predicted, age ≥ 50 years, body mass
index (BMI) ≤ 23 kg/m2, presence of chronic bacterial infection by potentially
pathogenic microorganisms and macroscopic appearance of the sputum
(mucous vs mucopurulent or purulent)
Fig. 2 Probability of the isolation of non-tuberculous mycobacteria in patients with non-cystic fibrosis bronchiectasis by patients characteristics.
Prob = probability; BMI = body mass index
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and with higher rates of A. fumigatus culture in patients
with CF [21, 23, 27] than in NTM-negative patients. Given
that airway colonization by filamentous fungi has been as-
sociated with older age in CF patients with bronchiectasis
[28, 29], perhaps the more frequent isolation of Aspergillus
could be explained by the older age of NTM-positive
patients in our study.
One of the key strengths of the present study is the very
large cohort of patients with multiple sputum samples
during the 5-year follow-up and the fact that we were able
to construct an individual probability tree for the presence
of bronchiectasis depending on the characteristics of the
patient. Also noteworthy is the association with better pul-
monary function and a trend towards an association with
lower frequency of chronic infection by P. aeruginosa.
Furthermore, in other studies on bronchiectasis and
NTM, the study population was entered from a single ter-
tiary referral center, while ours is the only multicenter
study with a large patient population.
In addition to the logical restraints inherent to a retro-
spective design, our study is limited by the fact that the
only factors we found to be clearly associated with isola-
tion of NTM were age, lung function, and BMI. This
finding may have been due to underpowering, since only
18 patients were NTM-positive. Furthermore, since we
did not perform bronchoscopy, we could have underesti-
mated the prevalence of NTM.
Conclusions
In conclusion, we report an 8.3 % prevalence of NTM
(2.3 % meeting ATS/IDS microbiological criteria for in-
fection) in the sputum of screened non-CF patients with
bronchiectasis in specialist clinics. M. avium complex
appears to be the most common pulmonary NTM in
this group of patients. Patients who are culture-positive
for NTM are older and have a lower BMI and milder
disease in functional terms. They also tend to have less
frequent chronic infection by P. aeruginosa and more
frequent isolation of A. fumigatus than culture-negative
patients. Larger sample sizes will enable us to better
evaluate the extent of the association of bronchiectasis
with NTM, assess the clinical impact of the disease, and
identify factors that are clearly associated with NTM in
non-CF patients with bronchiectasis.
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